Abstract:Abstract Background On a worldwide basis, the prevalence of hepatocellular carcinoma (HCC) is twice as much in the past two decades, which is the third most common cause in cancer deaths. Therefore there is still an urgent need for new drugs with greater validity against HCC. Autophagy, which is essential in the intracellular clearance of many proteins and organelles, has been closely related to cancer generation and development. Generally, p53 is recognized as a pro-autophagic factor in a transcription-dependent pattern and also an important factor in the progress of HCC. As a selective substrate for autophagy, p62 is a key factor in tumorigenesis on account of its crucial roles in the control of cellular events. Now that small molecule compound-0404 was defined as a DNA-damaging reagent by the p53 pathway, our work aims to examine whether 0404 can affect p53-dependent autophagy and its positive effect in the treatment of HCC. Methods The anti-cancer activity of 0404 was examined in vitro. In the HepG2 cells and Huh7 cells, the apoptosis was detected by Flow Cytometry, while cell viability was measured by the CCK8 Assay. The Hela eGFP-LC3 cells, which express fusion protein combined light chain 3 (LC3) with enhanced Green Fluorescent Protein (eGFP), were treated with 0404 at various concentrations for various time points. HepG2 cells were treated with 0404 at various concentrations (5.0 nM, 20 nM, and 50 nM) for 24h. Autophagy was identified by eGFP-labeled LC3. And the expression levels of autophagy-associated proteins, such as mammalian target of rapamycin (mTOR), phospho-mTOR (p-mTOR), p62 and LC3B, were tested by Western Blotting. Results We confirmed that 0404 could inhibit the proliferation of HepG2 and Huh7 in a dose-dependent manner, and compared to Huh7 cells with mutant p53, HepG2 cells with wild-type p53 were more sensitive to 0404 treatment for apoptosis. We also found that 0404 promoted the development of autophagy in a dose- and time-dependent manner. Compared with untreated group, LC3 in 0404-treated groups resided primarily in the cytoplasm including cytoplasmic puncta indicative of autophagosomes. Simultaneously, the expression levels of mTOR and p62 were down-regulation, while the LC3B expression level was up-regulation by 0404-treatment. And the expression level of p-mTOR was down-regulation in a dose-dependent in HepG2 cells. Conclusion These results show clearly that DNA-damaging reagent-0404 can effectively inhibit HCC through p53-dependent autophagy. Acknowledgment This work was supported by the National Natural Science Foundation of China (81272679) and the Major national S&T Projects (2013ZX09041003). Citation Format: Min Zheng, Bingjue Ye, Guohua Lou, Caixia Xia, Weiyang Zheng, Yanning Yanning, Xiao Xu, Yongchao Zhao, Long Mao, Wanghong Xu. DNA-damaging reagent -0404 effectively inhibits hepatocellular carcinoma through p53-dependent autophagy. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3546.

Cantharidin Inhibits Proliferation of Liver Cancer by Inducing DNA Damage via KDM4A-Dependent Histone H3K36 Demethylation

Cantharidin Inhibits Cell Proliferation and Induces Apoptosis Through G2/M Phase Cell Cycle Arrest in Hepatocellular Carcinoma Stem Cells.

Cantharidin Induces DNA Damage and Inhibits DNA Repair-Associated Protein Expressions in TSGH8301 Human Bladder Cancer Cell.

Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS Via Mitochondria-Dependent Pathway.

Cantharidin Induces DNA Damage and Inhibits DNA Repair-Associated Protein Levels in NCI-H460 Human Lung Cancer Cells

The Radiotherapy-Sensitization Effect of Cantharidin: Mechanisms Involving Cell Cycle Regulation, Enhanced DNA Damage, and Inhibited DNA Damage Repair

Cantharidin Exerts Anti-Hepatocellular Carcinoma by Mir-214 Modulating Macrophage Polarization

Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response

Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner

cDNA microarray analysis of the effect of cantharidin on DNA damage, cell cycle and apoptosis-associated gene expression in NCI-H460 human lung cancer cells in vitro

Cantharidin induces apoptosis of human pancreatic cancer cells:an experimental study

Abstract 3546: DNA-damaging Reagent -0404 Effectively Inhibits Hepatocellular Carcinoma Through P53-Dependent Autophagy

Study on Cantharidin Reversing the Drug-resistance of Nonsmall Cell Lung Cancer to DDP by Regulating the Expression of PD-L1

Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma

Cantharidin Reverses Multidrug Resistance of Human Hepatoma Hepg2/Adm Cells Via Down-Regulation of P-Glycoprotein Expression

Anticancer Effects of Cantharidin in A431 Human Skin Cancer (epidermoid Carcinoma) Cells in Vitro and in Vivo

Cantharidin Inhibits the Growth and Invasion Ability of Pancreatic Cancer Cells and the Mechanism

Inhibitory effect of cantharidin from meloids on laryngeal carcinoma cell lines and gastric carcinoma cell lines

Effect of norcantharidin on proliferation and apoptosis of hepatoma HepG2 cells

Analysis of Gene Expression Profiles in Human Hl-60 Cell Exposed to Cantharidin Using Cdna Microarray

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo